Europe Single-use Bioreactors Market: Accelerating Biopharmaceutical Innovation and Growth

• By Product: The market is segmented into single-use bioreactor systems, media bags, filtration assemblies, and other products. In 2024, single-use bioreactor systems are expected to hold the largest share, driven by benefits such as reduced cleaning requirements, increased flexibility, smaller footprint, lower capital investment, and minimized risk of cross-contamination. The demand from biopharma companies aiming to reduce costs further fuels the growth of this segment.

• By Type: The stirred-tank bioreactors segment is projected to dominate in 2024, owing to their extensive use for CHO cell lines and suspension cultures in large-volume bioproduction. Their advanced designs over traditional systems also contribute to their growth.

• By Cell Type: The mammalian cells segment is expected to account for the largest share in 2024. Mammalian cells are widely used in both commercial and research bioproduction, especially for developing complex biomolecules like monoclonal antibodies and therapeutic proteins. Their extensive use in clinical research further supports market growth.

• By Application: The commercial bio-production segment is expected to dominate in 2024, driven by the increasing production of biosimilars, rising cases of genetic and rare diseases, and government support for vaccine development and immunization programs.

• By End User: Contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) are expected to register the highest CAGR during the forecast period. This growth is attributed to the growing trend of outsourcing by pharmaceutical and biopharmaceutical companies, along with CDMOs’ expansion strategies. For example, in July 2021, Viralgen VC (Spain) launched a new facility in Basque, Italy, focused on adeno-associated virus gene therapy production.